EUVIMEDScopri EUVIMED
Open access · CC BY-NC 4.0

In silico assessment of cellular damage from Lu‐177, Ac‐225, and Pb‐212 therapeutic radionuclides

Konstantinos P Chatzipapas, Konstantinos Papachristou, Dimitris Visvikis, Sebastien Incerti, John D Hazle, George C Kagadis iD

Medical Physics · 2025-11 · 52 (11)

DOI: 10.1002/mp.70089 ↗

At a glance

Journal article in Medical Physics, published online on 2025-10-27. Written by Konstantinos P Chatzipapas and 5 co-authors. Institution: Department of Radiation Science and Technology, Delft University of Technology, Delft, Netherlands. Major MEDLINE topics: Lutetium, Radioisotopes, Computer Simulation, Actinium. Cited 6 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Hellenic Foundation for Research and Innovation (H.F.R.I.), European Union's EURATOM research and innovation program, Dutch Ministry of Economic Affairs.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Targeted radionuclide therapy (TRT) has emerged as a unique and effective treatment modality for cancer. Monte Carlo simulations have greatly advanced investigations into radiation‐caused DNA damage, including the complexity of this damage.

Purpose

This study aimed to evaluate DNA damage induced by high‐linear energy transfer therapeutic radionuclides used in TRT, specifically 225 Ac, 177 Lu, and 212 Pb, using Geant4‐DNA Monte Carlo simulations.

Methods

The Geant4‐DNA toolkit, incorporating the “molecularDNA” example, was employed to simulate radiation interactions within a human fibroblast cell model featuring a fractal chromatin fiber geometry within an ellipsoidal nucleus. Three source geometries (membrane, cytoplasm, nucleus) were modeled to assess the impact of radionuclide localization. Key metrics, including absorbed dose, double‐strand break (DSB) yield, single‐strand break/DSB ratio, and DSB/Gbp/decay, were calculated for 225 Ac (alpha emitter), 177 Lu (beta emitter), and 212 Pb (mixed alpha/beta emitter). Simulations accounted for physical, physicochemical, and chemical stages, with validation against published data for 177 Lu and 225 Ac.

Results

Alpha emitter 225 Ac exhibited the highest DSB/Gbp/decay (1.646 in nucleus geometry) and absorbed dose (0.256 Gy/decay), followed by 212 Pb (0.455 DSB/Gbp/decay, 0.0684 Gy/decay), and 177 Lu (0.0058 DSB/Gbp/decay, 0.0007 Gy/decay). DSB yields increased with proximity to the nucleus, with 225 Ac showing up to 284 times greater DSB/Gbp/decay than 177 Lu. Validation showed < 10% divergence from reference studies.

Conclusions

Geant4‐DNA simulations highlight the superior radiobiological effectiveness of alpha emitters, particularly 225 Ac, for inducing DNA damage and emphasize the importance of source localization. These findings enhance our understanding of TRT's radiobiological effects and can be used to support development of refined therapeutic strategies.

Subjects

MeSH terms (MEDLINE)

LutetiumRadioisotopesComputer SimulationActiniumLead RadioisotopesDNA DamageHumansMonte Carlo MethodDNA Breaks, Double-StrandedFibroblasts

Author keywords

Geant4‐DNAMonte Carlo simulationsdosimetrymolecular radiotherapyradionuclide therapy

Substances

LutetiumRadioisotopesActiniumLutetium-177Lead RadioisotopesActinium-225

Authors and institutions

  • Department of Radiation Science and Technology, Delft University of Technology, Delft, Netherlands.
  • Laboratoire de Traitement de l'Information Médicale (LaTIM), UMR 1101, INSERM, University of Brest, Brest, France.
  • 3DMI Research Group, Department of Medical Physics, School of Medicine, University of Patras, Rion, Greece.
  • Laboratoire de Physique des 2 infinis de Bordeaux (LP2IB), UMR 5797, CNRS, University of Bordeaux, Gradignan, France.
  • Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID profiles: George C Kagadis

Funding

  • Hellenic Foundation for Research and Innovation (H.F.R.I.)
  • European Union's EURATOM research and innovation program
  • Dutch Ministry of Economic Affairs

Cite

APA

Chatzipapas, K. P., Papachristou, K., Visvikis, D., Incerti, S., Hazle, J. D., & Kagadis, G. C. (2025). In silico assessment of cellular damage from Lu‐177, Ac‐225, and Pb‐212 therapeutic radionuclides. Medical Physics, 52(11). https://doi.org/10.1002/mp.70089

Vancouver

Chatzipapas KP, Papachristou K, Visvikis D, Incerti S, Hazle JD, Kagadis GC. In silico assessment of cellular damage from Lu‐177, Ac‐225, and Pb‐212 therapeutic radionuclides. Medical Physics. 2025;52(11). doi:10.1002/mp.70089

BibTeX
@article{Chatzipapas2025,
  author = {Chatzipapas, Konstantinos P and Papachristou, Konstantinos and Visvikis, Dimitris and Incerti, Sebastien and Hazle, John D and Kagadis, George C},
  title = {In silico assessment of cellular damage from Lu‐177, Ac‐225, and Pb‐212 therapeutic radionuclides},
  journal = {Medical Physics},
  year = {2025},
  volume = {52},
  number = {11},
  doi = {10.1002/mp.70089}
}
Start for free →